IMMUNE-MEDIATED HYPOTHYROIDISM

This adverse event was reported 1128 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED HYPOTHYROIDISM:

# Drug Count
0 PEMBROLIZUMAB 701
1 NIVOLUMAB 319
2 CARBOPLATIN 286
3 IPILIMUMAB 210
4 PACLITAXEL 183
5 PACLITAXEL (AIBUMIN-BOUND) 177
6 LENVATINIB 98
7 PEMETREXED DISODIUM 78
8 CISPLATIN 69
9 CYCLOPHOSPHAMIDE 69
See all common drugs associated with IMMUNE-MEDIATED HYPOTHYROIDISM

IMMUNE-MEDIATED HYPOTHYROIDISM is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PEMBROLIZUMAB 701 0.0065
1 IPILIMUMAB 210 0.0048
2 DOSTARLIMAB 11 0.0044
3 FOSNETUPITANT AND PALONOSETRON 5 0.0042
4 NETUPITANT AND PALONOSETRON 5 0.0042
5 NIVOLUMAB 319 0.0033
6 LENVATINIB 98 0.0029
7 TREMELIMUMAB 11 0.0025
8 CARBOPLATIN 286 0.0022
9 DURVALUMAB 45 0.0021
See all drugs enriched for association with IMMUNE-MEDIATED HYPOTHYROIDISM